Evaluation of costs for cystoid macular edema among patients after cataract surgery

Jordana K. Schmier, Michael Halpern, David W. Covert, G. Philip Matthews

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

PURPOSE: Little is known about the costs of cystoid macular edema (CME), an important complication associated with cataract surgery. The purpose of this analysis was to estimate the cost of treatment for CME in the United States. METHODS: Data were analyzed from the 1997 through 2001 Medicare 5% Beneficiary Encrypted Files. Beneficiaries who underwent cataract surgery were identified and stratified by diagnosis of CME (cases) or no diagnosis of CME (controls) within 1 year after surgery. Claims and reimbursements for ophthalmic care were identified. Subgroup analyses explored CME costs among beneficiaries with diabetes versus those without diabetes. RESULTS: Of 139,759 beneficiaries with cataract surgery, 1.95% (2,720) were diagnosed with CME. Annual total ophthalmic claims were 41% ($3,298) higher for cases than for controls; payments were 47% ($1,092) higher (both P < 0.0001). Approximately 16% (23,122) of cataract patients had diabetes. The rate of CME diagnosis was significantly higher for diabetics than for nondiabetics (3.05% vs. 1.73%, respectively). Differences in claims and payments between cases and controls were similar for diabetic and nondiabetic subgroups. CONCLUSION: CME is associated with substantial costs. Therapies that prevent or decrease CME severity are likely to result in cost savings, particularly among diabetic beneficiaries. Further analyses should explore the relationship of comorbidities to costs among CME patients.

Original languageEnglish (US)
Pages (from-to)621-628
Number of pages8
JournalRetina
Volume27
Issue number5
DOIs
StatePublished - Jun 2007
Externally publishedYes

Fingerprint

Macular Edema
Cataract
Costs and Cost Analysis
Cost Savings
Medicare
Health Care Costs
Comorbidity

Keywords

  • Claims analysis
  • Costs and cost analysis
  • Cystoid macular edema

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

Evaluation of costs for cystoid macular edema among patients after cataract surgery. / Schmier, Jordana K.; Halpern, Michael; Covert, David W.; Matthews, G. Philip.

In: Retina, Vol. 27, No. 5, 06.2007, p. 621-628.

Research output: Contribution to journalArticle

Schmier, Jordana K. ; Halpern, Michael ; Covert, David W. ; Matthews, G. Philip. / Evaluation of costs for cystoid macular edema among patients after cataract surgery. In: Retina. 2007 ; Vol. 27, No. 5. pp. 621-628.
@article{3d643472a9234f9a906b2496590e41cc,
title = "Evaluation of costs for cystoid macular edema among patients after cataract surgery",
abstract = "PURPOSE: Little is known about the costs of cystoid macular edema (CME), an important complication associated with cataract surgery. The purpose of this analysis was to estimate the cost of treatment for CME in the United States. METHODS: Data were analyzed from the 1997 through 2001 Medicare 5{\%} Beneficiary Encrypted Files. Beneficiaries who underwent cataract surgery were identified and stratified by diagnosis of CME (cases) or no diagnosis of CME (controls) within 1 year after surgery. Claims and reimbursements for ophthalmic care were identified. Subgroup analyses explored CME costs among beneficiaries with diabetes versus those without diabetes. RESULTS: Of 139,759 beneficiaries with cataract surgery, 1.95{\%} (2,720) were diagnosed with CME. Annual total ophthalmic claims were 41{\%} ($3,298) higher for cases than for controls; payments were 47{\%} ($1,092) higher (both P < 0.0001). Approximately 16{\%} (23,122) of cataract patients had diabetes. The rate of CME diagnosis was significantly higher for diabetics than for nondiabetics (3.05{\%} vs. 1.73{\%}, respectively). Differences in claims and payments between cases and controls were similar for diabetic and nondiabetic subgroups. CONCLUSION: CME is associated with substantial costs. Therapies that prevent or decrease CME severity are likely to result in cost savings, particularly among diabetic beneficiaries. Further analyses should explore the relationship of comorbidities to costs among CME patients.",
keywords = "Claims analysis, Costs and cost analysis, Cystoid macular edema",
author = "Schmier, {Jordana K.} and Michael Halpern and Covert, {David W.} and Matthews, {G. Philip}",
year = "2007",
month = "6",
doi = "10.1097/01.iae.0000249577.92800.c0",
language = "English (US)",
volume = "27",
pages = "621--628",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Evaluation of costs for cystoid macular edema among patients after cataract surgery

AU - Schmier, Jordana K.

AU - Halpern, Michael

AU - Covert, David W.

AU - Matthews, G. Philip

PY - 2007/6

Y1 - 2007/6

N2 - PURPOSE: Little is known about the costs of cystoid macular edema (CME), an important complication associated with cataract surgery. The purpose of this analysis was to estimate the cost of treatment for CME in the United States. METHODS: Data were analyzed from the 1997 through 2001 Medicare 5% Beneficiary Encrypted Files. Beneficiaries who underwent cataract surgery were identified and stratified by diagnosis of CME (cases) or no diagnosis of CME (controls) within 1 year after surgery. Claims and reimbursements for ophthalmic care were identified. Subgroup analyses explored CME costs among beneficiaries with diabetes versus those without diabetes. RESULTS: Of 139,759 beneficiaries with cataract surgery, 1.95% (2,720) were diagnosed with CME. Annual total ophthalmic claims were 41% ($3,298) higher for cases than for controls; payments were 47% ($1,092) higher (both P < 0.0001). Approximately 16% (23,122) of cataract patients had diabetes. The rate of CME diagnosis was significantly higher for diabetics than for nondiabetics (3.05% vs. 1.73%, respectively). Differences in claims and payments between cases and controls were similar for diabetic and nondiabetic subgroups. CONCLUSION: CME is associated with substantial costs. Therapies that prevent or decrease CME severity are likely to result in cost savings, particularly among diabetic beneficiaries. Further analyses should explore the relationship of comorbidities to costs among CME patients.

AB - PURPOSE: Little is known about the costs of cystoid macular edema (CME), an important complication associated with cataract surgery. The purpose of this analysis was to estimate the cost of treatment for CME in the United States. METHODS: Data were analyzed from the 1997 through 2001 Medicare 5% Beneficiary Encrypted Files. Beneficiaries who underwent cataract surgery were identified and stratified by diagnosis of CME (cases) or no diagnosis of CME (controls) within 1 year after surgery. Claims and reimbursements for ophthalmic care were identified. Subgroup analyses explored CME costs among beneficiaries with diabetes versus those without diabetes. RESULTS: Of 139,759 beneficiaries with cataract surgery, 1.95% (2,720) were diagnosed with CME. Annual total ophthalmic claims were 41% ($3,298) higher for cases than for controls; payments were 47% ($1,092) higher (both P < 0.0001). Approximately 16% (23,122) of cataract patients had diabetes. The rate of CME diagnosis was significantly higher for diabetics than for nondiabetics (3.05% vs. 1.73%, respectively). Differences in claims and payments between cases and controls were similar for diabetic and nondiabetic subgroups. CONCLUSION: CME is associated with substantial costs. Therapies that prevent or decrease CME severity are likely to result in cost savings, particularly among diabetic beneficiaries. Further analyses should explore the relationship of comorbidities to costs among CME patients.

KW - Claims analysis

KW - Costs and cost analysis

KW - Cystoid macular edema

UR - http://www.scopus.com/inward/record.url?scp=34250155661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250155661&partnerID=8YFLogxK

U2 - 10.1097/01.iae.0000249577.92800.c0

DO - 10.1097/01.iae.0000249577.92800.c0

M3 - Article

VL - 27

SP - 621

EP - 628

JO - Retina

JF - Retina

SN - 0275-004X

IS - 5

ER -